When a company raises money, either an initial public offering or follow-up offering, the offering may include DRs. The inclusion of DRs may broaden the shareholder base of the company.

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and the deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to the issuer to reimburse and / or share revenue from the fees collected from DR holders, or waive fees and expenses to the issuer for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon as depositary may use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

Ratio DR:Ord	DR Price Date	DR Price (USD)	US / Non-US / Total DRs Placed	US / Non-US / Total DR Captial Raised (USD)	Pvtzn.	Dep. Bank	Industry	Country	Region
1:13	Jan 17, 2018	101.00	7,920,800 0 7,920,800	800,000,800 0 800,000,800	N	CIT	Pharma. & Biotech.	China	North Asia
1:13	Aug 16, 2017	71.00	2,834,750 0 2,834,750	201,267,250 0 201,267,250	N	CIT	Pharma. & Biotech.	China	North Asia
1:13	Nov 23, 2016	32.00	7,100,000 0 7,100,000	227,200,000 0 227,200,000	N	CIT	Pharma. & Biotech.	China	North Asia
1:13	Feb 03, 2016	24.00	7,590,000 0 7,590,000	182,160,000 0 182,160,000	N	CIT	Pharma. & Biotech.	China	North Asia